Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576

Rhea-AI Filing Summary

Context Therapeutics Inc. director Stacey Jennifer Evans received a stock option grant covering 45,000 shares of common stock. The option has an exercise price of $0.576 per share and was awarded as a compensation-related grant, not an open-market purchase.

The option vests and becomes exercisable on the earlier of June 24, 2027, or the company’s 2027 annual meeting of stockholders, subject to her continued service with the company. Following this grant, Evans holds stock options for 45,000 shares directly under this award.

Insights

Equity compensation analyst

Director received a routine stock option grant with future vesting conditions.

Director Stacey Jennifer Evans was granted options over 45,000 shares of Context Therapeutics common stock at an exercise price of $0.576 per share. This is coded as an acquisition (grant/award), indicating standard equity compensation rather than a market trade.

The option vests on the earlier of June 24, 2027 or the issuer’s 2027 annual meeting of stockholders, contingent on continued service. Because there are no open‑market buys or sells and the scale is not compared to overall ownership, this looks like routine governance-related compensation with neutral investment signal.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stacey Jennifer Evans

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	45,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 45,000 shares (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Key Figures

Option grant size: 45,000 shares Exercise price: $0.576 per share Vesting date trigger: June 24, 2027 +1 more

4 metrics

Option grant size 45,000 shares Stock option covering common stock granted to director

Exercise price $0.576 per share Exercise price of newly granted stock option

Vesting date trigger June 24, 2027 Latest vesting date; earlier if 2027 annual meeting occurs first

Expiration date June 23, 2036 Option expiration for the 45,000-share grant

Key Terms

Stock Option (right to buy), exercise price, expiration date, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 0.5760"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders"

FAQ

What did Stacey Jennifer Evans report in the CNTX Form 4 filing?

Stacey Jennifer Evans reported receiving a stock option grant for 45,000 shares of Context Therapeutics common stock. The award is a compensation-related option, not an open-market stock purchase or sale, and reflects her role as a director of the company.

What is the exercise price of Stacey Evans’ new Context Therapeutics options?

The new stock options granted to Stacey Evans have an exercise price of $0.576 per share. This is the price she would pay per share to convert the options into Context Therapeutics common stock once the options are vested and exercisable.

When do Stacey Evans’ Context Therapeutics options vest?

The options vest on the earlier of June 24, 2027 or Context Therapeutics’ 2027 annual stockholders meeting. Vesting is also conditioned on Stacey Evans’ continued service with the company through that date, aligning incentives with long-term governance.

How many Context Therapeutics shares are covered by Stacey Evans’ new options?

The grant covers 45,000 shares of Context Therapeutics common stock. These shares are not issued immediately; they become available only if the options vest and Stacey Evans chooses to exercise them by paying the $0.576 per-share exercise price.

Does the CNTX Form 4 show Stacey Evans buying or selling shares in the market?

The filing does not show any open-market buying or selling by Stacey Evans. It reports only a grant of stock options as compensation, which is categorized as an acquisition of a derivative security rather than a purchase or sale of existing common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 04:22 PM Accepted by SEC EDGAR 06/26/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stacey Jennifer Evans

(Last) (First) (Middle)

2001 MARKET STREET

SUITE 3915, UNIT #15

(Street)

PHILADELPHIA PENNSYLVANIA 19103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.576	06/24/2026		A		45,000		(1)	06/23/2036	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Remarks:

	/s/ Alex Levit, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)